Crestone
Crestone, Inc. is a Boulder, Colorado–based clinical-stage biopharmaceutical company developing novel-mechanism small-molecule antibacterials. The company’s pipeline targets Clostridioides difficile infection, antibiotic-resistant Gram-positive infections, and mycobacterial diseases (NTM/TB). Activities described on the site include discovery and lead optimization, preclinical in vivo testing, clinical trial execution (Phase 1–2, with Phase 3 planning), chemistry scale-up and stability testing, microbiome and multi-omics analyses, and engagement with government funders (NIH/NIAID).
Industries
Nr. of Employees
medium (51-250)
Crestone
Patents
Substituted phenylether-thienopyridone compounds with antibacterial activity
US-8697720-B2
View Details5-[3-((R)(-)-5,7-Dibromo-1,2,3,4-tetrahydro-naphthalen-1-ylamino)-propylamino]-4H-thieno[3,2-b]pyridine-7-one; optically active; new target antibiotic, inhibitor of bacterial methionyl tRNA synthetase; antibiotic resistance; Clostridium difficile infection; mostly in immunodeficient, elderly
US-7973050-B2
View Details
Substituted phenylether-thienopyridone compounds with antibacterial activity
US-8697720-B2
View Details5-[3-((R)(-)-5,7-Dibromo-1,2,3,4-tetrahydro-naphthalen-1-ylamino)-propylamino]-4H-thieno[3,2-b]pyridine-7-one; optically active; new target antibiotic, inhibitor of bacterial methionyl tRNA synthetase; antibiotic resistance; Clostridium difficile infection; mostly in immunodeficient, elderly
US-7973050-B2
View DetailsProducts
CRS3123 (clinical candidate for C. difficile infection)
Orally dosed small‑molecule inhibitor of methionyl‑tRNA synthetase developed to treat Clostridioides difficile infection; mechanism inhibits growth, toxin production and sporulation while sparing much of normal gut microbiota.
CRS0540 (preclinical candidate for Gram‑positive infections)
Preclinical small‑molecule antibacterial targeting PolC (replicative DNA polymerase) with broad activity against clinically significant Gram‑positive pathogens including MRSA, PRSP, VRE and others; oral bioavailability described in preclinical data.
CRS0393 (preclinical candidate for NTM and TB)
Preclinical benzothiazole‑amide class anti‑mycobacterial candidate targeting MmpL3 (cell wall synthesis) with activity against nontuberculous mycobacteria and Mycobacterium tuberculosis; reported oral bioavailability and in vivo efficacy in mouse models.
CRS700010
Antiviral compound candidate assessed for activity against respiratory and select viral agents.
CRS700072
Broad-spectrum antiviral compound candidate with potent activity against RSV and Measles.
CRS700062
Broad-spectrum antiviral compound candidate active against respiratory syncytial virus and other select agents.
CRS3123 (clinical candidate for C. difficile infection)
Orally dosed small‑molecule inhibitor of methionyl‑tRNA synthetase developed to treat Clostridioides difficile infection; mechanism inhibits growth, toxin production and sporulation while sparing much of normal gut microbiota.
CRS0540 (preclinical candidate for Gram‑positive infections)
Preclinical small‑molecule antibacterial targeting PolC (replicative DNA polymerase) with broad activity against clinically significant Gram‑positive pathogens including MRSA, PRSP, VRE and others; oral bioavailability described in preclinical data.
CRS0393 (preclinical candidate for NTM and TB)
Preclinical benzothiazole‑amide class anti‑mycobacterial candidate targeting MmpL3 (cell wall synthesis) with activity against nontuberculous mycobacteria and Mycobacterium tuberculosis; reported oral bioavailability and in vivo efficacy in mouse models.
CRS700010
Antiviral compound candidate assessed for activity against respiratory and select viral agents.
CRS700072
Broad-spectrum antiviral compound candidate with potent activity against RSV and Measles.
CRS700062
Broad-spectrum antiviral compound candidate active against respiratory syncytial virus and other select agents.
Services
Synthesis and analog design, chemical process development and scale‑up, analytical support (LC‑MS, NMR), and cGMP API experience provided on a contract basis.
Microbiological profiling including susceptibility testing performed according to CLSI guidelines.
Synthesis and analog design, chemical process development and scale‑up, analytical support (LC‑MS, NMR), and cGMP API experience provided on a contract basis.
Microbiological profiling including susceptibility testing performed according to CLSI guidelines.
Expertise Areas
- Antibacterial small‑molecule drug discovery
- Clinical trial management and operations
- Medicinal chemistry and chemical process development
- Preclinical pharmacology and toxicology
Key Technologies
- Methionyl‑tRNA synthetase inhibition (MetRS targeting)
- PolC (replicative DNA polymerase) inhibition
- MmpL3 inhibition (anti‑mycobacterial mechanism)
- Multi‑omics (metagenomics and untargeted metabolomics)
News & Updates
Conference presentations showcasing clinical and Phase 1/2 data for the C. difficile candidate and multi‑omics findings.
Peer‑reviewed publication reporting Phase 2 randomized controlled trial results demonstrating safety, tolerability, clinical cure rates comparable to vancomycin and lower recurrence at Day 40 for the CRS3123 candidate.
Announcement summarizing Phase 2 results, multi‑omics gut microbiome analyses, improved synthetic process, extended stability testing and Phase 3 planning; cites NIH/NIAID support.
Phase 2 RCT (NCT04781387) reported clinical cure rates of 97% for the investigational candidate (combined doses) vs 93% for vancomycin and recurrence at Day 40 of 4% vs 23% for vancomycin; study described as randomized, double‑blind, vancomycin‑controlled and multicenter.
Multiple NIH/NIAID grants and contracts funded the Phase 2 study and follow‑on microbiome analyses; the site reports more than $50 million in R&D grants and contracts overall and cites NIAID contract No. 75N93019C00056.
Conference presentations showcasing clinical and Phase 1/2 data for the C. difficile candidate and multi‑omics findings.
Peer‑reviewed publication reporting Phase 2 randomized controlled trial results demonstrating safety, tolerability, clinical cure rates comparable to vancomycin and lower recurrence at Day 40 for the CRS3123 candidate.
Announcement summarizing Phase 2 results, multi‑omics gut microbiome analyses, improved synthetic process, extended stability testing and Phase 3 planning; cites NIH/NIAID support.
Phase 2 RCT (NCT04781387) reported clinical cure rates of 97% for the investigational candidate (combined doses) vs 93% for vancomycin and recurrence at Day 40 of 4% vs 23% for vancomycin; study described as randomized, double‑blind, vancomycin‑controlled and multicenter.
Multiple NIH/NIAID grants and contracts funded the Phase 2 study and follow‑on microbiome analyses; the site reports more than $50 million in R&D grants and contracts overall and cites NIAID contract No. 75N93019C00056.